Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Antiepileptic agent reported by Parke-Davis

Dec. 2, 1996

Ethical's sustained-release morphine sublicensed for Canada

Dec. 2, 1996

CytoTherapeutics and Genentech sign new CNS therapeutics agreement

Nov. 29, 1996

Vertex compound effective in rat model of nerve injury

Nov. 29, 1996

New serotoninergic drugs from E. Merck

Nov. 29, 1996

Merck & Co. describes new compounds for dopamine-related disorders

Nov. 29, 1996

Zeneca submits antimigraine Rx for approval

Nov. 28, 1996

Novel anticonvulsant described by SmithKline Beecham

Nov. 28, 1996

First approval for Aricept

Nov. 27, 1996

Fujisawa antidementia agent in clinical stage

Nov. 27, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.